iifl-logo

Piramal Pharma Ltd Profit & Loss Statement

229.2
(4.64%)
Mar 25, 2025|02:59:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Piramal Pharma : related Articles

Piramal Pharma unit gets approval to market Neoatricon in UK
21 Mar 2025|11:14 AM

Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.

Read More
Piramal Pharma’s Turbhe Facility Gets US FDA Observations
18 Feb 2025|11:02 PM

This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.

Read More
Piramal Pharma Q3 Profit Drops 63% YoY, Revenue Up 12.5%
29 Jan 2025|11:11 PM

In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.

Read More
Piramal Pharma Launches Chlorpromazine Injection in US Market
23 Jan 2025|12:06 PM

As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.

Read More
Piramal Enterprises Invests ₹1,000 Crore in Subsidiary PCHFL for Growth
31 Dec 2024|09:48 PM

The transaction falls in the internal transaction category because the parent is trading with a subsidiary.

Read More
Piramal Pharma Invests $85M to Fuel Growth, Eyes $2B Revenue by FY30
27 Oct 2024|05:05 PM

Piramal Pharma Solutions (PPS) is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky, USA, projected for completion by FY27.

Read More
Piramal Pharma logs 350% y-o-y growth in Q2 net profit
24 Oct 2024|02:30 PM

Piramal Pharma Limited's Chairperson, Nandini Piramal, attributed the company's development to its solid operational performance.

Read More
Piramal Pharma Ahmedabad facility gets EIR from USFDA
30 Sep 2024|07:48 PM

On September 11, 2024, and October 26, 2023, the stock reached a 52-week high of ₹244.10 and a low of ₹87.55.

Read More
Top 10 stocks for today – 15th July, 2024
15 Jul 2024|08:59 AM

Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.